Description

Adalimumab, marketed as HUMIRA, is a recombinant human IgG1 monoclonal antibody that binds and neutralizes tumor necrosis factor?alpha (TNF??), a key mediator in autoimmune inflammation. This 40?mg/0.4?ml formulation in a prefilled pen is widely used in research to model cytokine blockade, TNF?driven signaling, and immune modulation studies. This high?purity product is ideal for in vitro and in vivo investigation of chronic inflammatory and autoimmune mechanisms. For research use only.

Product Specifications

Mechanism of Action & Research Applications

HUMIRA (Adalimumab Injection) neutralizes TNF??, inhibiting downstream NF??B signaling and reducing pro-inflammatory cytokine expression. Widely utilized in research to model inflammatory pathways, arthritis models, cytokine storm, and immunotherapeutic interventions. Its subcutaneous delivery via prefilled pen enables precise dosing and study of pharmacokinetics in chronic inflammatory models

Side Effects (For Reference Only in Research Models)

Based on clinical analogs, potential observed effects include injection-site discomfort, upper respiratory infections, mild rash, headache, and rare immunological reactions. Severe effects observed in therapeutic settings include serious infection risk, reactivation of hepatitis B, demyelinating disorders, heart failure, and hematologic complications. These insights can guide safety assessments in model design

Disclaimer

HUMIRA (Adalimumab Injection) is strictly intended for laboratory research use only. Not for human or veterinary therapeutic or diagnostic use.